Navigation Links
Medarex Reviews Recent Highlights and Outlook for 2009
Date:1/13/2009

PRINCETON, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today provided an overview of the company's strong science-base and strategy for maximizing the value of its product portfolio. Also provided were recent highlights of Medarex's record of achievements in 2008, as well as its expected outlook for product pipeline milestones in 2009, underscoring Medarex's dedication to creating multiple opportunities for long-term value through the development of commercially attractive product candidates for cancer, inflammation and infectious diseases. In addition, updated full-year 2008 financial guidance was presented by Medarex's Chairman and CEO, Howard H. Pien.

Financial Guidance Update

Medarex is committed to the consistent management of resources and increased efficiencies that steadily support its research and development efforts across the organization. For the full year of 2008, Medarex currently expects a cash burn rate per month of approximately $12.2 million, a decrease from previous guidance for a monthly 2008 cash burn rate of approximately $12.4 million. This guidance includes Medarex's continual investment in its pipeline and the net contributions to the ipilimumab program. Medarex expects its monthly cash burn rate per month for the full year of 2009 to remain largely consistent with full-year 2008 net cash burn.

Medarex plans to disclose its 2008 full-year financial results and financial guidance for 2009 the week of February 23, 2009. Factors that may cause variations in Medarex's projected earnings and financial performance and other risks and uncertainties are discussed in the section below entitled "Statement on Cautionary Factors" and in our filings with the U.S. Securities and Exchange Commission.

Webcast

The webcast of Medarex's presentation from
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... ,, NEW YORK, Dec. 14 /PRNewswire-USNewswire/ ... study (MTF) -- the largest survey on teen drug ... -- underscores that teens, intentional abuse of prescription (Rx) ... for concern, with an alarming number of young people ... ,, Teen Abuse of Medication Continues to ...
(Date:12/14/2009)... 14 The Hemophilia Federation of America ... issues involving the Teamsters Local 929 and the ... national blood system depends on skilled workers to ... is distilled into products such as clotting factor ... disease. ,, The Division of Blood Services ...
(Date:12/14/2009)... Exercise benefited men whose disease had been treated, hadn,t ... -- Exercise appears to reduce the risk of death ... study, which began in January 1986, included 668 men ... stage III colon cancer that had not spread (nonmetastatic ... that asked them about any new cancer and disease ...
(Date:12/14/2009)... protection, study finds, , , MONDAY, Dec. 14 (HealthDay News) ... their morning without a cup or two of java: ... developing type 2 diabetes. , That,s the conclusion ... coffee you drink, the lower your risk of diabetes. ... percent reduction in the risk of diabetes, the researchers ...
(Date:12/14/2009)... are underdiagnosed, poorly treated and highly stigmatized, according ... H. Rubin, M.D., Ph.D. So these Washington University ... problems. , In "Demystifying Psychiatry," Zorumski and Rubin, ... treating psychiatric patients and helping patient families, say ... and treatment result from a lack of understanding ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:HFA Voices Blood Safety Concerns 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3
... Environmentalists want bisphenol A banned from products for infants ... organizations in the United States and Canada are calling ... bisphenol A (BPA) in baby bottles, toddler sippy cups, ... "This is quite concerning. All 19 polycarbonate bottles [investigated ...
... be getting an,unfair rap for disrupting women,s sleep at ... increase during the,transition into menopause, reinforcing the idea that ... in sleep laboratories, the,connection between hot flashes and sleep ... Women,s Health Watch., A new study concludes that ...
... -- A new study by researchers at Northwestern University,s ... how best to treat patients in respiratory distress in ... believed that high levels of carbon dioxide (CO2) or ... acute lung disease may be beneficial to them. Now, ...
... LAS VEGAS, Feb. 7 American Pacific,Corporation (Nasdaq: ... quarter ended December 31, 2007., We provide non-GAAP ... A reconciliation of the non-GAAP measures to the most ... data., FINANCIAL HIGHLIGHTS, Quarter Ended December 31, ...
... episode, OAKLAND, Calif., Feb. 7 Nytera Tilmon ... care for her seven children,all of whom live with ... a new television show revealing Nytera,s story and others,behind ... is,called "Union Time" and it,s the only national labor-produced ...
... After just seven months in print, Cell Stem Cell, ... New Journal - Science, Technology & Medicine, by the Professional ... Publishers (AAP). , This honor, which is among the Association ... a year after Cell Stem Cell published its first issue ...
Other Medicine News:Health News:Report Shows Dangerous Chemical Can Leach From Baby Bottles 2Health News:Report Shows Dangerous Chemical Can Leach From Baby Bottles 3Health News:Hot Flashes Not Always to Blame for Sleep Problems in Menopausal Women, Reports the Harvard Women's Health Watch 2Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 2Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 3Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 4Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 5Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 6Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 7Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 8Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 9Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 10Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 11Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 12Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 13Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 14Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 15Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 16Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 17Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 18Health News:American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter 19Health News:Cell Stem Cell named 'Best New Journal' of 2007 2
(Date:12/14/2009)... CHICAGO, Dec. 14 Sword Diagnostics, Inc. ... Patent Office (USPTO) has issued patent number ... Biological Organisms using Raman Scattering" to the company. ... on improved sensitivity. ,, "The issuance of ... move forward with our continued development and commercialization," ...
(Date:12/14/2009)... Dec. 14 Cardium Therapeutics (NYSE Amex: ... 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment ... Healing: Science and Industry Conference held December 10-13, ... The conference is attended by top industry leaders ... wound healing. Dr. Barbara K. Sosnowski, Cardium,s ...
(Date:12/14/2009)... Dec. 14 Authentidate Holding Corp. ... of secure Health Information Exchange and workflow ... of the Carolinas ("HCC"), a home health ... durable medical equipment supplier, have selected Authentidate,s ... standardize processes for the completion of patient ...
Breaking Medicine Technology:Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 2Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 3Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 4Heart Attacks Less Often Fatal Today 49550 1Heart Attacks Less Often Fatal Today 49550 2Heart Attacks Less Often Fatal Today 49550 3EUROPACE raises remote monitoring profile 49546 1EUROPACE raises remote monitoring profile 49546 2EUROPACE raises remote monitoring profile 49546 3Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 1Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 2
... 1 C. Larry Pope, President and Chief Executive ... ), sent the following update to all employees on ... joint venture operation in Veracruz:To Our Employees:The media continues ... minute-to-minute basis, and while we would like to accommodate ...
... Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: ... quarterly royalty payment of approximately $1.5 million from ... for the treatment of Alzheimer,s disease. Under an ... payments on certain sales of Memantine by Merz ...
Other Medicine Technology:Smithfield Sends Update to Employees on Testing Process at Veracruz Joint Venture 2
CVC 223 is an assayed quality control material used for confirming the calibration and linearity of CO-Oximeter instrumentation....
... assayed quality control material used for monitoring the ... It is for specific use on Bayer analyzers ... 288, and 270) and the AVOX Systems CO-Oximeters ... used on the IRMA TRUpoint®. CC 527 is ...
... QC 623 is an assayed quality control material ... available in four (4) levels for monitoring analyzer ... It may be used on multiple test analyzers ... the Radiometer 600). QC623 is also for use ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Medicine Products: